Will RFK Jr.’s peptide push bolster the gray market for obesity drugs?
With competition fierce in the weight loss space, a potential change to how the FDA classifies peptides could increase pressure in the market even more.
By PharmaVoice
· Apr 10, 2026
· via PharmaVoice
Tags
policyformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
PolicyFierceBiotech ↗
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma ex…
PolicyFierceBiotech ↗
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump adm…
PolicyBriefing
Using the Kemp-Kasten amendment, the administration withheld $32.5 million in FY2025 UNFPA support and is expe…